Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections
Ezra R. Miller(Pulmonary and Critical Care Associates), Gary M. Hunninghake(Hubei University of Science and Technology), Rachel K. Putman(Brigham and Women's Hospital), Yin P. Hung(Harvard University), George R. Washko(Brigham and Women's Hospital), Hiroto Hatabu(Harvard University), Mizuki Nishino(Brigham and Women's Hospital), Marina Vivero(Brigham and Women's Hospital), Lynette M. Sholl(Brigham and Women's Hospital), Tetsuro Araki(Brigham and Women's Hospital), Iván O. Rosas(Brigham and Women's Hospital)
American Journal of Respiratory and Critical Care Medicine
September 21, 2017
Cited by 110
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
|American Journal of Respiratory and Critical Care Medicine|2010|1k
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
|JAMA Oncology|2016|750
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
|Nature Genetics|2018|701